ClinicalTrials.gg
TerminatedNCT06008483Updated Jul 23, 2026

A Dose Finding Study to Treat Bone Tumor(s)

A Phase 1 interventional study of 153-Sm-DOTMP (Samarium-153-DOTMP) in Bone Cancer, Bone Tumor and Solid Tumor, sponsored by QSAM Therapeutics, Inc.. Terminated at 4 sites in United States. Open to participants aged 15 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by QSAM Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Change in development program indication

From the registry’s dates

  • Primary completion was Aug 2024, 2 years 3 months ago, and no results have been posted to the registry.
  • Registered 1 year 3 months after the study started (first participant enrolled Apr 2022, registered Aug 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
15 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 113 studies in Bone Neoplasms with a site in United States — 23 open to participants now, 37 under way, 1 of them phase 3. Bone Neoplasms · United States.

Enrollment
72nd of 84
5 · median 35
Started
2022
with 4 others
Phase 1
23 of 113
2 open now
Registered
96th of 113
by date

Among the 113 studies in Bone Neoplasms with a site in United States, this one is the 72nd largest by enrollment of the 84 interventional ones that give a count, is one of 5 that started in 2022, is one of 23 in phase 1, and was the 96th registered.

Bone Neoplasms

259 studies on the registry are indexed under Bone Neoplasms; 69 are open to participants now.

Browse Bone Neoplasms studies →

Open to participants now

23 of the 113 studies in Bone Neoplasms with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Bone Neoplasms studies recruiting now, 34 (64%) set no upper age limit and 13 (25%) stop at 75 or younger; 24 take children under 18; 4 take healthy volunteers.

This study: 15 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Bone Neoplasms with a site in United States, or all of them as a file.
02

Study summary

To determine the Maximum Tolerated Dose (MTD) of CycloSam®, Samarium-153-DOTMP (Sm-153-DOTMP), a radiopharmaceutical that delivers radiation to the bone when injected, given as a tandemly administered pair of doses to subjects with one or more solid tumor(s) in the bone or metastatic solid tumors to the bone that are visible on bone scan.

Read the detailed description

This is an open-label, unblinded, multi-center, dose-finding study of 153-Sm-DOTMP (CycloSam®), a radiopharmaceutical that delivers radiation to the bone when injected, to identify the MTD of 153-Sm- DOTMP, given as a tandemly administered pair of doses to subjects with solid tumors visible on bone scan. The MTD will be defined as the dose level that produces a dose limiting toxicity (DLT) rate no greater than 25%. DLTs will be defined as any grade 3 or greater hematologic or nonhematologic toxicity, as defined by the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE), experienced during a 42 day observation window. Clinical response will be defined as either stable disease (SD) or a decrease in the size of the tumor by radiographic imaging (which may include computed tomography [CT] or magnetic resonance imaging [MRI]) using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.The Day 1 dose will remain constant at 0.5 mCi/kg, with the Day 8 dose escalated from 0.5 mCi/kg (dose level 1) to 1.0 mCi/kg (dose level 2) to 2.0 mCi/kg (dose level 3) and then to 3.0 mCi/kg (dose level 4).

03

Conditions studied

  • Bone Cancer
  • Bone Tumor
  • Solid Tumor
  • Metastatic Cancer to the Bone
  • Metastatic Tumor to the Bone

Browse trials for

Keywords

  • Bone cancer
  • Bone Tumor
  • Solid Tumor
  • Metastatic Cancer to the Bone
  • Metastatic Tumor to the Bone
04

Who can participate

Ages eligible
15 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects will be between the ages of 15 and 75, inclusive.
  2. Subjects must have a confirmed diagnosis of a solid tumor to bone, or a histologically confirmed diagnosis of a solid tumor to the bone or metastatic to the bone.
  3. Subjects must have on anatomic imaging that is also avid for phosphonate compounds as demonstrated by a positive 99mTc diphosphonate bone scan. Not all lesions must be positive on bone scan.
  4. Adequate organ function, including:

    i. Adequate renal function, defined as a measured >70 mL/min/1.73 m2 or normal radioisotope (GFR).

    ii. Adequate hematologic function, defined as a count >100,000 cells/mm3 and an (ANC) >1,000 cells/mm3.

  5. of at least eight weeks.
  6. performance status >50%.
  7. Subjects must have adequately recovered from the effects of any prior chemotherapy, as determined by the treating physician and study team, based in part on organ function defined above. Toxicities from previous therapies must have recovered to v5.0 grade ≤1. Subjects with Grade 2 anemia per CTCAE v5.0 will be permitted as long as the subject has normal cardiac function.
  8. Adequate cardiac function. Subjects with previously identified cardiac disease will be eligible, as 153Sm-DOTMP is not expected to cause cardiac dysfunction and is only expected to result in very transient hypocalcemia.
  9. A stem cell product collected either by peripheral stem cell mobilization or bone marrow harvest prior to the infusion of CycloSam® must be available, prior to trial entry. A minimum of 2 x 106 CD34+ cells/kg ideal body weight are required.
  10. Female subjects of (defined as premenopausal and capable of becoming pregnant) must have a negative serum pregnancy test at the Screening visit. Females must be surgically sterile, for at least one year prior to Screening (no other medical cause involved) with a Follicle Stimulating Hormone (FSH) level of greater than 40 mIU/mL or must be using a highly effective method of and agree to its use for at least 30 days following the last dose of 153Sm-DOTMP. Highly effective methods of contraceptive are defined as tubal ligation or an approved hormonal contraceptive such as oral contraceptives, patches, implants, injections, rings, or hormonally-impregnated intrauterine device.
  11. Male subjects with partners of child-bearing potential must agree to use highly effective methods of contraception for at least 90 days after the last dose of 153Sm-DOTMP.
  12. The subject and/or the subject's legally authorized guardian, if the subject is a minor, must acknowledge in writing that to become a study subject has been obtained, in accordance with institutional policies approved by the U.S. Department of Health and Human Services.
  13. Subjects must have previously received effective treatment for their underlying disease and have no potentially curative options available.
  14. The concurrent use of hormonal therapies or bisphosphonates is acceptable, provided the latter do not render target lesions invisible on 99mTc bone scan. Subjects will have the option to re-screen up to once more after seven days if they do not initially meet all of the inclusion criteria

Exclusion criteria

Exclusion Criteria:

  1. Subject is pregnant or breastfeeding.
  2. Subject is sexually active and does not agree to use accepted, effective forms of .
  3. Subject has received prior radiotherapy to all known areas of current active disease.
  4. Subject has a (BMI) > 50 kg/m2.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Other
    Dose Level 1

    Everyone gets a first dose of 0.5 mCi/kg dose and then in 7 days a second dose of 0.5 mCi/kg

    Drug: 153-Sm-DOTMP (Samarium-153-DOTMP)

  • Other
    Dose Level 2

    Everyone gets a first dose of 0.5 mCi/kg dose and then in 7 days a second dose of 1.0 mCi/kg

    Drug: 153-Sm-DOTMP (Samarium-153-DOTMP)

  • Other
    Dose Level 3

    Everyone gets a first dose of 0.5 mCi/kg dose and then in 7 days a second dose of 2.0 mCi/kg

    Drug: 153-Sm-DOTMP (Samarium-153-DOTMP)

  • Other
    Dose Level 4

    Everyone gets a first dose of 0.5 mCi/kg dose and then in 7 days a second dose of 3.0 mCi/kg

    Drug: 153-Sm-DOTMP (Samarium-153-DOTMP)

Interventions

  • This is an open-label, unblinded, multi-center, dose-finding study of 153Sm-DOTMP (CycloSam®) to identify the MTD of 153Sm- DOTMP, given as a tandemly administered pair of doses to subjects with solid tumors visible on bone scan.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity Rate (DLT)

    The primary endpoint is defined as the DLT rate observed during a 42-day window following administration of 153-Sm-DOTMP for each dose level. DLTs will be defined as any grade 3 or greater hematologic or nonhematologic toxicity, as defined by the National Cancer Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE), experienced during a 42 day observation window. The MTD (Maximum Tolerated Dose) will be defined as the dose level that produces a dose limiting toxicity (DLT) rate no greater than 25%.

    Time frame: 42 Days

Secondary outcomes

  1. Bone Tumor Efficacy - Clinical Response Rate

    Clinical response rate - defined as either SD or a decrease in the size of the tumor by radiographic imaging (which may include CT or MRI) using RECIST v1.1 criteria with the tumor measured in mm by days and months.

    Time frame: Day 42, 68, 4 months, 8 months, 12 months, 24 months, and 36 months

  2. Overall Survival

    Overall survival - defined as the time from start of treatment to death due to any cause as measured in days and months

    Time frame: Day 38, 42, 68, 4 months, 6 months, 8 months, 12 months, 24 months, and 36 months

  3. Time to Progression

    Time to progression - defined as the time from start of treatment to appearance of new lesions or expansion of current lesions by 20% as per RECIST v1.1 criteria in mm of tumor and by days and months

    Time frame: Day 42, 68, 4 months, 8 months, 12 months, 24 months, and 36 months

  4. Pain Palliation

    Pain palliation as assessed per the pain VAS as measured in mm of length of a 100 mm Visual Analog Pain Scale by days and months

    Time frame: Day 38, 42, 68, 4 months, 6 months, 8 months, 12 months, 24 months, and 36 months

  5. Safety Based on Number of Treatment Emergent Adverse Events

    Safety based on the number of Treatment Emergent Adverse event (TEAEs), as measured by the number of these events by days and months.

    Time frame: Day 38, 42, 68, 4 months, 6 months, 8 months, 12 months, 24 months, and 36 months

07

Study locations

4 sites
  • Clinical Trial Site
    Chicago, Illinois 60616, United States
  • Clinical Trial Site
    Columbia, Missouri 65212, United States
  • Clinical Trial Site
    New Brunswick, New Jersey 08901, United States
  • Clinical Trial Site
    Houston, Texas 77024, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2022 to primary completion in Aug 2024, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2023
First posted
Aug 23, 2023
StartActual
Apr 5, 2022
Primary completionActual
Aug 8, 2024
CompletionActual
Aug 8, 2024
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06008483
Lead sponsor
QSAM Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 23, 2023
Start date
Apr 5, 2022
Primary completion
Aug 8, 2024
Completion
Aug 8, 2024
Last update
Jul 23, 2026

Study contacts

Barry Sugarman
study director · QSAM Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dotmp SM-153

Start the discussion